Private Equity

NurExone appoints Eyal Gabbai, a healthcare and finance heavyweight, to its board, signaling a strategic pivot from R&D to market execution for its therapies.

Legendary investor Eric Sprott injects $40M into Highlander Silver, fueling its world-class San Luis project and signaling a major move in the silver market.

S. Penny Windle Kline, a top litigator, joins SEDA's board in a move to dominate the complex financial litigation and expert witness market.

With a major cash infusion, NeOnc Technologies is set to accelerate its promising therapies aimed at conquering the elusive blood-brain barrier.

Disney hires top Morgan Stanley analyst Benjamin Swinburne, signaling a strategic pivot to embed Wall Street's perspective directly into its core leadership.

With national security clearance secured, silicon carbide leader Wolfspeed completes its restructuring, forging a powerful alliance with Japan's Renesas.

As SmartStop sets its Q4 earnings date, investors watch to see if its aggressive expansion and acquisition spree can translate into sustained profitability.

A $10M investment from pharma giant Dr. Reddy’s validates Coya Therapeutics' novel ALS drug, funding the path to commercial-scale manufacturing.

Bonaccord Capital Partners' new award highlights its success in the booming GP stakes market and validates parent company P10's strategic middle-market focus.

Sundream's acquisition of Atlantic Plumbing Services signals a major consolidation trend in home services, blending local legacy with regional platform growth.

Nexstar Media Group maintains its robust dividend, signaling confidence while channeling cash towards its massive $6.2 billion acquisition of TEGNA.

Tonix Pharmaceuticals' newly approved drug, TONMYA, offers a breakthrough for millions, using unique science to combat the chronic pain of fibromyalgia.

Lexicon Pharmaceuticals raised nearly $95 million to fund its drug pipeline, but the move sent its stock plunging as investors weighed future promise against immediate dilution.

NB Private Equity Partners caps 2025 with strong realizations, aggressive share buybacks, and new investments, showcasing a dynamic private equity strategy.

After teetering on the brink, Poxel SA has secured court approval for a complex recovery plan, offering a lifeline for its innovative metabolic drug pipeline.

FCP's sale of a 28-acre site to developer Kane Realty Corp. for $72.3M signals the next major redevelopment phase for Raleigh's booming North Hills.

In the heart of oil country, a new boom is taking shape. New Era Energy & Digital is building a gigawatt-scale AI campus, but can it win the infrastructure race?

Cadrenal Therapeutics acquires a novel Phase 2 drug for a deadly clotting disorder, a strategic move targeting an underserved $1 billion market.

Roivant Sciences reveals accelerated timelines for key drugs and a bold three-year growth plan, pivoting its unique 'Vant' model toward commercialization.

byNordic Acquisition Corp. buys another month in its search for a Nordic tech merger, but each extension drains funds and tests investor patience.